Study Type :
Interventional  (Clinical Trial)
Estimated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
Up to 3 cohorts are planned, with each cohort receiving one of 3 different treatment doses
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Double-masked, placebo-controlled
Primary Purpose:
Treatment
Official Title:
A Phase 1b, Randomized, Double-Masked, Placebo-Controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of VB421 in Subjects With Thyroid Eye Disease (TED)
Estimated Study Start Date :
January 2023
Estimated Primary Completion Date :
September 2023
Estimated Study Completion Date :
December 2023
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
